Profile Design leads aerobar count at Miami International Triathlon

first_imgAccording to Profile Design its aerobars dominated an official aerobar count taken from the transition area of the Miami International Triathlon, held on 15 March 2009. Profile Design aerobars led with 371, a 42% share of the count and more than double that of second placed Vision, which had a count of 180 or 20% of the total.Profile Design was particularly pleased with the results of the aerobar count as it was title sponsor of the race, alongside Aqua Sphere, Quintana Roo as official bike brand and official nutrition brand Hammer Nutrition.The official aerobar count taken from transition area saw aerobars dominate overall within the Olympic distance triathlon race. Branded aerobars represented a count of 683 and a 76% share, compared to no aerobars used or unknown bars.Profile Design – 371 Vision – 180 None – 165 Unknown – 45 Zipp – 37 Syntace – 24 Bontrager – 16 HED – 15 Easton – 14 Oval Concepts – 9 Deda – 4 Felt – 4 Blackwell Research – 4 Ritchey – 2 Pro – 1 3T – 1 Devox – 1www.mitriathlon.com www.profile-design.com Relatedlast_img read more

Vega petitions for Bar reinstatement

first_img August 15, 2009 Regular News V ega petitions for Bar reinstatementPursuant to Rule 3-7.10, Sergio Vega has petitioned the Florida Supreme Court for Bar reinstatement.On July 2, 2002, Vega was emergency suspended for mishandling of trust funds. As a result, on May 17, 2004, Vega received a three year suspension to run nunc pro tunc July 2, 2002.Any persons having knowledge bearing upon Vega’s fitness or qualifications to resume the practice of law should contact Randi Klayman Lazarus, Bar Counsel, The Florida Bar, Suite M-100, 444 Brickell Avenue, Miami 33131, phone (305) 377-4445. Vega petitions for Bar reinstatementlast_img

The Freight Co offers emergency flood recovery logistics services

first_imgAs well as teaming up with this company The Freight Co will also independently support affected companies to re-build their businesses by offering temporary warehousing, emergency import freight and customs clearance services, trucking machinery and stocked items to dry locations and relocating factories and machinery. These services will for the time being charged at cost to support rebuilding the affected industries, says The Freight Co.”We believe that this is the best way to support the community, help rebuild industry and regenerate some of the hundreds of thousands of lost jobs in these difficult times,” said Harm Emaus, regional director VIP Accounts of The Freight Co Thailand. “We are certain that with our task force team and our resources we can assist affected companies around the clock to find solutions for their growing numbers of problems created by the worst floods in decades.”The Freight Co is a Bangkok, Thailand-based company founded in 1996 with offices in Thailand and Vietnam, providing heavy transportation services and installation in Cambodia, Laos, Myanmar, Thailand and Vietnam.last_img read more

Read of the Week

first_imgWhen Breath Becomes AirPaul KalanithiThe Bodley HeadReview: Chantel ErfortThere’s nothing quite as sad as reading a book, knowing from the get-go, that the main protagonist is going to die.But before you get upset with me for revealing this, don’t worry: it doesn’t ruin one word of the story. Instead, it makes every moment spent reading this book, all the more special, with the reader being given an intimate look into a life coming to an end. And as the writer opts to focus on life instead of his impending death, so too, does he lure the reader away from obsessing over whether his death will come on this page, or the next, or the next.The protagonist in question is the writer himself, Paul Kalanithi, a brilliant young neurosurgery specialist in the final years of his residency, who penned When Breath Becomes Air in the final years of his life.Paul was in his prime as a medical professional, young, married and in love, when he was diagnosed with terminal cancer.As skilled with the English language as he was with his medical instruments, Paul tells a deeply touching tale of a doctor who suddenly finds the shoe on the other foot, having to learn to be patient – and a patient – and to entrust decisions no man should have to make about his own life, to his doctor.Having recently had someone close to me undergo several neurosurgical procedures, I have found myself seeking out books on the topic, hungry to understand how so much can go wrong when the brain is affected – and what drives the men and women who specialise in a kind of surgery so delicate. While in Do No Harm, David Marsh, a surgeon at the end of his career, was able to look back at his younger self with a sense of confidence and critically assess the mistakes he had made, Paul writes with the passion and urgency of a young doctor pursuing his life’s dream with the acute knowledge that it may soon escape his grasp.He writes with tenderness about his relationship with his wife Lucy, with the relationship between them almost taking on a life of its own and becoming a character in its own right.A scholar of both literature and medicine, Paul’s reflections on his illness and neurosurgery are philosophical and insightful.When Breath Becomes Air is beautifully written, uncluttered by dramatic descriptions of, or unnecessary build-ups to, life-changing events. Paul’s writing is sincere and his style of storytelling, gentle. And when he finally slipped away, though the moment was understated, I truly felt sad but all the richer for having read this remarkable man’s reflections on death and the true meaning of life.last_img read more

Medicare incurs more than 12 billion over prostate cancer care in older

first_img Source:https://unclineberger.org/news/prostate-cancer-care-for-older-men Reviewed by James Ives, M.Psych. (Editor)Sep 14 2018Researchers from the University of North Carolina Lineberger Comprehensive Cancer Center estimate that screening for and treating prostate cancer in men aged 70 years or older, which is not recommended by national guidelines, cost Medicare more than $1.2 billion over a three year period for each group of men diagnosed in the United States each year.Published in the journal JAMA Oncology, the study examined the costs associated with screening for prostate cancer, including treatment, for three years after diagnosis. They estimated that for men diagnosed in each of 2004, 2005, 2006, and 2007, the total cost for treating and screening for each group would be $1.2 billion for three years after diagnosis. The study also showed that of the total, $451 million was spent on men who were diagnosed with prostate cancer that is graded with a Gleason score of 6, which is considered to be low-grade disease and best managed using active surveillance rather than aggressive treatment.”The tough discussions that happen in health economics are often cases where care is beneficial, but costly. That’s a hard trade-off, but this one is actually easier than that,” said UNC Lineberger’s Justin Trogdon, PhD, associate professor of health policy management in the UNC Gillings School of Global Public Health, and the study’s first author. “This is a scenario where care is probably not beneficial and also costly, and we are putting a dollar figure on just how costly this is.”The researchers said there is a wide recognition that screening for prostate cancer should stop in men at age 70. The U.S. Preventive Services Task Force recommends against prostate cancer screening in men above age 70, citing, among other reasons, that the harms from screening are “at least moderate” or greater for men in that age group because of risk of false-positives, harms from biopsy, and harms from treatment, which can include sexual dysfunction and urinary incontinence.”For patients who are diagnosed with prostate cancer at an older age, because the cancer is often slow-growing, it is unlikely to be the cause of their mortality,” said UNC Lineberger’s Ronald C. Chen, MD, MPH, associate professor in the UNC School of Medicine Department of Radiation Oncology and the study’s corresponding author. “So, we are not only spending U.S. health care dollars diagnosing an issue that probably isn’t going to be a problem for patients, but when we treat these patients who don’t need treatment, they suffer unnecessary side effects like urinary incontinence or sexual dysfunction.”Related StoriesSugary drinks linked to cancer finds studyUsing machine learning algorithm to accurately diagnose breast cancerTrends in colonoscopy rates not aligned with increase in early onset colorectal cancerFor the retrospective study, researchers used the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER)-Medicare linked claims database to analyze costs related to diagnosis and work-up, treatment, follow-up, and side-effect management for nearly 50,000 men 70 years of age or older who were diagnosed with prostate cancer between 2004 and 2007. They estimated the cost of diagnosing and treating men for three years after diagnosis because that’s a typical time frame for patients to receive treatment in.They found that for men diagnosed in each year, the total three-year cost was $1.2 billion. For men diagnosed in 2004, for example, their estimated cost to Medicare would be $1.2 billion across three years. The median per-patient cost within three years after prostate cancer diagnosis was $14,453, with treatment costs accounting for 73 percent of that total. The researchers estimated a cost savings of $320 million per year for Medicare if patients who have a Gleason score of 6 choose active surveillance.”Studies indicate that we are testing for prostate cancer in people for whom the potential harms outweigh the potential benefits, and then we are treating – actually over treating – people for a cancer that may have little to no impact on their life expectancy,” Chen said. “Not following guidelines could be putting people’s health at risk, and it is costing the U.S. health care system a lot of money. It would make more sense to put these resources into other areas that could do more good for patients.”Researchers write in the study that foregoing aggressive treatment of low-risk prostate cancer in older patients, especially those with other health issues, could prevent harm due to treatment-related side effects, while also providing a savings to Medicare. They suggest that screening men with at least a 10-year life expectancy, and selectively treating those with more aggressive cancer may be one approach to eliminate unnecessary spending while maximizing patient outcomes.last_img read more